Previous studies in HR deficient ovarian and breast cancers that have acquired resistance to platinum chemotherapy and/or PARP inhibitor [53, 54] have implicated those genes enriched at collapsed replication forks during ATR inhibition [55]. This evidence concerns the gene ATR and breast carcinoma.